Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.
Copyright © 2021 Aventis Pharma Limited. All rights reserved.
Great Britain Summary of Product Characteristics Northern and Republic of Ireland Summary of Product Characteristics
Terms of Use | Privacy Policy | Cookies Policy | Site Map | Contact Us
MAT-IE-2101043(v5.0) | Date of preparation: January 2022
DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
DUPIXENT can be used with or without topical corticosteroids.
Contraindications: hypersensitivity to DUPIXENT or to any ingredient in the formulation.
Other relevant warnings and precautions regarding: driving or operating machinery; systemic hypersensitivity reactions; live vaccines; conjunctivitis and keratitis; helminth infection; concomitant atopic conditions; pregnant and nursing women; geriatric patients.
Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.
Indication and clinical use:
DUPIXENT (dupilumab injection) is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.
• No dose adjustment is recommended for elderly patients.
• Safety and efficacy in pediatric patients have not been established.
Contraindications:
Hypersensitivity to DUPIXENT or to any ingredient in the formulation or component of the container.
Warnings and precautions:
• Reduction of corticosteroid dosage
• Systemic hypersensitivity reactions
• Elevation of blood eosinophils
• Not studied with live vaccines
• Conjunctivitis and keratitis
• Patients with helminth infection
• Patients with comorbid asthma
• Pregnant and nursing women
• Geriatric patients
For more information:
Consult http://products.sanofi.ca/en/dupixent-en.pdf for important information relating to adverse drug reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-589-6215.
Please see DUPIXENT Product Monograph for complete prescribing information.
This link takes you to a third party website. Sanofi Genzyme has no control over the content of the website you are about to access. The terms of usage of the third party website will differ from that of the www.dupixent.co.uk. It is recommended that you carefully read the legal notice, cookies and privacy policy of third party websites before accessing these sites.
By continuing you are acknowledging that you have read this notice.
MAT-IE-2101043(v1.0) | Date of preparation: August 2021